Completing hepatitis C treatment cascade is still a challenge

During March, we interacted with a respondent who had completed re- treatment of his hepatitis C infection with Sofosbuvir/ velpatasvir for 12 weeks in 2023. But due to his frequent relapse to drug use he has not been able to conduct his sustained virologic response (SVR) test to ascertain if he has been cured form the infection.

Action Taken: The data enumerators provided counselling on the importance of SVR test and knowing the cure status. His blood samples were collected for the and delivered to the Jawaharlal Nehru Institute of Medical Sciences (JNIMS) which is also a model treatment centre under the national viral hepatitis control program the 6 th of March 2024.